Publisher
Springer Berlin Heidelberg
Reference105 articles.
1. Addington, J., & Duchak, V. (1997). Reasons for substance use in schizophrenia. Acta Psychiatrica Scandinavica, 96, 329–333.
2. Aderhold, V. (2015). Neuroleptika minimal. dosisabhängige risiken der medikamentösen therapie bei psychosen. PiD, 3, 75–80.
3. Ajdacic-Gross, V., Lauber, C., Warnke, I., Haker, H., Murray, R. M., & Rössler, W. (2007). Changing incidence of psychotic disorders among the young in Zurich. Schizophrenia Research, 95(1−3), 9–18.
4. Allebeck, P., Adamsson, C., Engstrom, A., & Rydberg, U. (1993). Cannabis and schizophrenia: A longitudinal study of cases treated in Stockholm County. Acta Psychiatrica Scandinavica, 88, 21–24.
5. Andreasson, S., Allebeck, P., Engstrom, A., & Rydberg, U. (1987). Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet, 2, 1483–1486.